Even though anakinra is currently approved for the therapy of rheumatoid arthritis and cryopyrin-associated periodic syndromes [169], off-label employment of anakinra in several other diseases, and the theoretical possibility of intervening in the progression of MGUS, or even in the therapy of MM with the use of anakinra, certainly appears fascinating. Here, NLRP3 is linked to Miyoshi myopathy.